Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Jinyu Bio-Technology Co's Debt-to-EBITDA or its related term are showing as below:
SHSE:600201'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.63
Current: 0.63
During the past 13 years, the highest Debt-to-EBITDA Ratio of Jinyu Bio-Technology Co was 0.63. The lowest was 0.00. And the median was 0.00.
SHSE:600201's Debt-to-EBITDA is ranked better than 61.74% of 311
companies
in the Biotechnology industry
Industry Median: 1.39
vs SHSE:600201: 0.63
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Jinyu Bio-Technology Co Debt-to-EBITDA Related Terms
Jinyu Bio-Technology Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600201 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Jinyu Bio-Technology Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jinyu Bio-Technology Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jinyu Bio-Technology Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Jinyu Bio-Technology Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Jinyu Bio-Technology Co (SHSE:600201) has a Debt-to-EBITDA of 0.75 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Jinyu Bio-Technology Co. According to the industry distribution chart, Jinyu Bio-Technology Co ranks #119 out of 311 companies in the Biotechnology industry, placing it in the top 38.3%.
Is Jinyu Bio-Technology Co's Debt-to-EBITDA too high?
Jinyu Bio-Technology Co's current Debt-to-EBITDA is 0.75. The Biotechnology industry median Debt-to-EBITDA is 1.39. Jinyu Bio-Technology Co's value of 0.75 is 46% below this industry median. Based on the distribution chart, Jinyu Bio-Technology Co ranks #119 out of 311 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jinyu Bio-Technology Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinyu Bio-Technology Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jinyu Bio-Technology Co ranks #119 out of 311 companies for Debt-to-EBITDA. This puts Jinyu Bio-Technology Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.39. Jinyu Bio-Technology Co's value of 0.75 is 46% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.39, based on 311 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jinyu Bio-Technology Co's current Debt-to-EBITDA of 0.75 is 46% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Jinyu Bio-Technology Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jinyu Bio-Technology Co's current Debt-to-EBITDA is 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinyu Bio-Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co (SHSE:600201) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.99, compared to a current price of ¥12.65 — trading 40.7% above its estimated fair value. The current Debt-to-EBITDA is 0.75 and 46% below the Biotechnology industry median of 1.39. Jinyu Bio-Technology Co's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Jinyu Bio-Technology Co (SHSE:600201), the current Debt-to-EBITDA is 0.75 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jinyu Bio-Technology Co (SHSE:600201) Overvalued in 2026?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co stock appears to be overvalued.
The current stock price of ¥12.65 is trading 40.7% above its estimated GF Value™ of ¥8.99.
GuruFocus considers Jinyu Bio-Technology Co to be Significantly Overvalued.
Key valuation signals for SHSE:600201:
Debt-to-EBITDA: 0.75
GF Value™: ¥8.99 vs. price of ¥12.65 (40.7% above fair value)
Industry Position: 46% below the Biotechnology median (#119 of 311)
No single metric tells the full story. See the SHSE:600201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.
62GF Score
Get the complete analysis for SHSE:600201
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600201 has been successfully added to your 
